A Phase I Trial of Pegylated Liposomal Doxorubicin (PLD), Carboplatin, Bevacizumab and Veliparib in Recurrent, Platinum-Sensitive Ovarian, Primary Peritoneal, and Fallopian Tube Cancer: An NRG Oncology/Gynecologic Oncology Group study

OBJECTIVE: To determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of veliparib combined with PLD and carboplatin (CD) in patients with recurrent, platinum-sensitive epithelial ovarian cancer. To determine the tolerability at the MTD combined with bevacizumab. METHODS: Pati...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Gynecol Oncol
Main Authors: Landrum, Lisa M., Brady, William E., Armstrong, Deborah K., Moore, Kathleen N., DiSilvestro, Paul A., O'Malley, David M., Tenney, Meaghan E., Rose, Peter G., Fracasso, Paula M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4724478/
https://ncbi.nlm.nih.gov/pubmed/26616225
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2015.11.024
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados